Innoveren Scientific（IVRN）株式概要イノベレン・サイエンティフィック社は、四肢救済のための再生医療技術を開発する医療バイオサイエンス企業である。 詳細IVRN ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析最新の財務報告は1年以上前のものである 株式の流動性は非常に低い 意味のある時価総額がありません ( $2K )すべてのリスクチェックを見るIVRN Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW481,888 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA481,888 investors already sharing narrativesYour Fair ValueUS$Current PriceUS$0.0002該当なし内在価値ディスカウントEst. Revenue$PastFuture-26m8m2016201920222025202620282031Revenue US$1.0Earnings US$0.2AdvancedSet Fair ValueView all narrativesInnoveren Scientific Inc. 競合他社Lipella PharmaceuticalsSymbol: OTCPK:LIPOMarket cap: US$924.0Vincerx PharmaSymbol: OTCPK:VINCMarket cap: US$66.5kSynairgenSymbol: OTCPK:SYGG.FMarket cap: US$110.3kProtoKinetixSymbol: OTCPK:PKTXMarket cap: US$164.7k価格と性能株価の高値、安値、推移の概要Innoveren Scientific過去の株価現在の株価US$0.000252週高値US$0.000752週安値US$0.000001ベータ01ヶ月の変化-71.43%3ヶ月変化-71.43%1年変化0%3年間の変化-99.90%5年間の変化-99.90%IPOからの変化-99.90%最新ニュースお知らせ • Aug 16Innoveren Scientific Inc. announced delayed 10-Q filingOn 08/15/2024, Innoveren Scientific Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 18Innoveren Scientific Inc. announced delayed 10-Q filingOn 05/16/2024, Innoveren Scientific Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 03Innoveren Scientific Inc. announced delayed annual 10-K filingOn 04/02/2024, Innoveren Scientific Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Mar 06Innoveren Scientific Announces 510(K) Submission to U.S. Federal Food and Drug Administration for Skindisc(Tm) LiteInnoveren Scientific Inc. announced that it has submitted a 510(k) premarket filing to the U.S. Federal Food and Drug Administration (FDA) for its SkinDiscTM Lite product. SkinDiscTM Lite provides an active and protein-rich cellular matrix that is essential for structural support and cellular attachment during the wound-healing process that can be administered in an outpatient setting. The product maintains complete wound contact and depth fill during the healing process, resulting in rapid growth of the host tissue. SkinDiscTM Lite utilizes autologous platelet-rich plasma (PRP) and platelet poor plasma concentrate, from the patient's own body, helping to mitigate any potential rejection of the product.お知らせ • Nov 17Innoveren Scientific Inc. announced delayed 10-Q filingOn 11/15/2023, Innoveren Scientific Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 18Innoveren Scientific Inc. announced delayed 10-Q filingOn 08/16/2023, Innoveren Scientific Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.最新情報をもっと見るRecent updatesお知らせ • Aug 16Innoveren Scientific Inc. announced delayed 10-Q filingOn 08/15/2024, Innoveren Scientific Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 18Innoveren Scientific Inc. announced delayed 10-Q filingOn 05/16/2024, Innoveren Scientific Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 03Innoveren Scientific Inc. announced delayed annual 10-K filingOn 04/02/2024, Innoveren Scientific Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Mar 06Innoveren Scientific Announces 510(K) Submission to U.S. Federal Food and Drug Administration for Skindisc(Tm) LiteInnoveren Scientific Inc. announced that it has submitted a 510(k) premarket filing to the U.S. Federal Food and Drug Administration (FDA) for its SkinDiscTM Lite product. SkinDiscTM Lite provides an active and protein-rich cellular matrix that is essential for structural support and cellular attachment during the wound-healing process that can be administered in an outpatient setting. The product maintains complete wound contact and depth fill during the healing process, resulting in rapid growth of the host tissue. SkinDiscTM Lite utilizes autologous platelet-rich plasma (PRP) and platelet poor plasma concentrate, from the patient's own body, helping to mitigate any potential rejection of the product.お知らせ • Nov 17Innoveren Scientific Inc. announced delayed 10-Q filingOn 11/15/2023, Innoveren Scientific Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 18Innoveren Scientific Inc. announced delayed 10-Q filingOn 08/16/2023, Innoveren Scientific Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 16H-CYTE, Inc. announced delayed 10-Q filingOn 05/15/2023, H-CYTE, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Dec 30H-CYTE, Inc. (OTCQB: HCYT) completed the acquisition of SkinDisc from Tanya Rhodes, Brock Liden, Spencer T Brown and Spencer T Brown.H-CYTE, Inc. (OTCQB: HCYT) entered into a letter of intent to acquire SkinDisc from Tanya Rhodes, Brock Liden, Spencer T Brown and Spencer T Brown for $2.3 million on September 19, 2022. H-CYTE, Inc. (OTCQB: HCYT) entered into a definitive agreement to acquire SkinDisc from Tanya Rhodes and others on December 22, 2022. H-CYTE, Inc. will pay an aggregate of 123,153 shares and earn out payment of $1.615 million. Both parties board approved the transaction. The transaction is expected to close within the next 30 days. Arthur Marcus of Sichenzia Ross Ference acted as legal advisor to H-CYTE. H-CYTE, Inc. (OTCQB: HCYT) completed the acquisition of SkinDisc from Tanya Rhodes, Brock Liden, Spencer T Brown and Spencer T Brown on December 28, 2022.お知らせ • Sep 20H-CYTE, Inc. (OTCQB: HCYT) entered into a letter of intent to acquire SkinDisc.H-CYTE, Inc. (OTCQB: HCYT) entered into a letter of intent to acquire SkinDisc on September 19, 2022. The transaction is expected to close within the next 30 days.お知らせ • Jan 12H-CYTE, Inc. (OTCPK:HCYT) entered into a letter of intent to acquire Catheter Precision, Inc.H-CYTE, Inc. (OTCPK:HCYT) entered into a letter of intent to acquire Catheter Precision, Inc. on January 11, 2022. The transaction is subject to a definitive agreement and customary closing conditions. The transaction is expected to close in the first quarter of 2022.お知らせ • Jun 30H-CYTE, Inc. Announces Publication of Positive Real-World Data Relating to the Use of Innovative Treatment at Helping Improve Overall Lung HealthH-CYTE, Inc. announced the publication of its clinical observational study titled, 'Longitudinal Assessment of FEV1 Change Following Autologous Cellular Therapy.' The study, published in the peer-reviewed Journal of Regenerative Medicine & Biology Research, relates to the Company’s innovative autologous treatment, and concludes that patients experienced a statistically significant improvement in pulmonary function at both 3 months and 12 months (FEV1 % predicted) and quality of life (CCQ score) post treatment. The study, which involved 281 participants with COPD (chronic obstructive pulmonary disease). demonstrated that 23% of patients saw an improvement in their lung function by at least 15% from baseline at 3 months post-treatment(FEV1 measures), and 29% of patients saw the same improvement at 12 months post-treatment. At 3 months and 12 months post-treatment, 64% and 67% of participants respectively, experienced a significant quality of life improvement. All participants tolerated the procedure well, and there were no reportable adverse or unexpected events. All participants were able to stay on their physician prescribed medications to manage their COPD. The efficacy, quality of life and safety shown in this study were above and beyond that achieved with their maintenance therapy. The data came from an externally validated patient database. The study design was observational following the intervention and therefore the limitations due to lack of a control group are recognized. To address this, a double blind randomized controlled trial involving the Company’s innovative PRP-PBMC therapy is currently being planned.お知らせ • Jan 21H-Cyte, Inc. Announces Board ChangesOn January 12, 2021, Mr. William Horne stepped down as Chairman of the board of directors of H-Cyte, Inc. Mr. Horne will remain a member of the Board. On January 12, 2021, Mr. Ray Monteleone was appointed the new Chairman of the Board. Mr. Monteleone is a current member of the Board.お知らせ • Oct 05H-CYTE, Inc. announced that it expects to receive $5.515765 million in funding from FWHC Bridge, LLC, FWHC Bridge Friends, LLCH-CYTE, Inc. (OTCPK:HCYT) announced that it has entered into a secured convertible note and warrant purchase agreement with FWHC Bridge, LLC and FWHC Bridge Friends, LLC to issue two secured convertible promissory notes in the original principal amount of $1,000,000 and $1,535,570 to FWHC Bridge, LLC and a secured convertible promissory note in the original principal amount of $100,000 to FWHC Bridge Friends, LLC to receive $2.635,570 in debt in the transaction. The notes are convertible into shares of the company. The company will issue common shares and option, warrant or other right to acquire another security in the transaction to receive $2,880,195 in the transaction pursuant to regulation D. The minimum investment accepted from any outside investor is $1,875. The company will receive 5,515,765 in total in the transaction.お知らせ • Oct 02H-CYTE, Inc. announced that it has received $2.880195 million in funding from FWHC Bridge, LLC, FWHC Bridge Friends, LLCOn May 5, 2020, H-CYTE, Inc. (OTCPK:HCYT) closed the transaction. The company amended the terms of the transaction. The company entered into a secured convertible note and warrant purchase agreement with FWHC Bridge, LLC and FWHC Bridge Friends, LLC. The company issued two secured convertible promissory notes in the original principal amount of $1,000,000 and $1,535,570 to FWHC Bridge, LLC and a secured convertible promissory note in the original principal amount of $100,000 to FWHC Bridge Friends, LLC to receive $2.635,570 in debt in the transaction. The notes are convertible into shares of the company. The company received $5,515,765 in the transaction. The transaction included participation from 32 investors pursuant to regulation D.お知らせ • Oct 01H-CYTE, Inc. Announces Executive ChangesH-CYTE, Inc. appointed Mr. Robert Greif as its and President. Mr. Greif is 55 years old. Prior to joining the Company, Mr. Greif was the Chief Commercial Officer and business development Leader at Axos Bio, Inc. from February 2019 to November 2019. At Axos, Mr. Greif built the north American commercial organization in preparation for the launch of a fist-in-class immunomodulatory. Prior to joining Atox, Mr. Greif led the commercial operations of rEvo Biologics, Inc., an orphan disease biotechnology company from May 2011 to February 2019. He also held a variety of business unit and commercial leadership roles at United health Group Incorporated, Boehringer Ingelheim Group and Sanofi SA. The Company believes that Mr. Greif's strong track record leading high-growth pharmaceutical and biotech businesses makes him qualified to serve in his role with the Company. On September 29, 2020, Ann Miller resigned as the Company's Chief Operating Officer. On September 29, 2020, Mr. William Horne resigned as the Company's President.お知らせ • Sep 30H-CYTE, Inc. Announces Executive ChangesH-CYTE, Inc. announced that Robert Greif has been named the company’s new chief executive officer. Most recently, he was Chief Commercial Officer and Business Development Leader at Atox Bio. Greif joins H-CYTE as CEO and President effective September 29, 2020. He replaces William E. Horne, who is stepping down as CEO but will remain on the company’s Board of Directors.株主還元IVRNUS BiotechsUS 市場7D0%6.5%2.7%1Y0%41.0%20.9%株主還元を見る業界別リターン: IVRN過去 1 年間で41 % の収益を上げたUS Biotechs業界を下回りました。リターン対市場: IVRNは、過去 1 年間で20.9 % のリターンを上げたUS市場を下回りました。価格変動Is IVRN's price volatile compared to industry and market?IVRN volatilityIVRN Average Weekly Movementn/aBiotechs Industry Average Movement10.1%Market Average Movement7.2%10% most volatile stocks in US Market16.2%10% least volatile stocks in US Market3.1%安定した株価: IVRNの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のIVRNのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/an/aMichael Yurkowskyinnoverenscientific.comイノベレン・サイエンティフィック社は、四肢救済のための再生医療技術を開発するメディカル・バイオサイエンス企業である。また、卵巣がん、膵がん、中皮腫の免疫療法も開発している。旧社名はH-CYTE, Inc.で、2023年7月にInnoveren Scientific Inc.に社名変更した。本社はフロリダ州タンパ。もっと見るInnoveren Scientific Inc. 基礎のまとめInnoveren Scientific の収益と売上を時価総額と比較するとどうか。IVRN 基礎統計学時価総額US$1.60k収益（TTM）-US$3.26m売上高(TTM)n/a0.0xP/Sレシオ0.0xPER（株価収益率IVRN は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計IVRN 損益計算書（TTM）収益US$0売上原価US$999.00売上総利益-US$999.00その他の費用US$3.26m収益-US$3.26m直近の収益報告Sep 30, 2023次回決算日該当なし一株当たり利益（EPS）0グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0.0%IVRN の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/10 22:47終値2026/07/21 00:00収益2023/09/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Innoveren Scientific Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Aug 16Innoveren Scientific Inc. announced delayed 10-Q filingOn 08/15/2024, Innoveren Scientific Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 18Innoveren Scientific Inc. announced delayed 10-Q filingOn 05/16/2024, Innoveren Scientific Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 03Innoveren Scientific Inc. announced delayed annual 10-K filingOn 04/02/2024, Innoveren Scientific Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Mar 06Innoveren Scientific Announces 510(K) Submission to U.S. Federal Food and Drug Administration for Skindisc(Tm) LiteInnoveren Scientific Inc. announced that it has submitted a 510(k) premarket filing to the U.S. Federal Food and Drug Administration (FDA) for its SkinDiscTM Lite product. SkinDiscTM Lite provides an active and protein-rich cellular matrix that is essential for structural support and cellular attachment during the wound-healing process that can be administered in an outpatient setting. The product maintains complete wound contact and depth fill during the healing process, resulting in rapid growth of the host tissue. SkinDiscTM Lite utilizes autologous platelet-rich plasma (PRP) and platelet poor plasma concentrate, from the patient's own body, helping to mitigate any potential rejection of the product.
お知らせ • Nov 17Innoveren Scientific Inc. announced delayed 10-Q filingOn 11/15/2023, Innoveren Scientific Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 18Innoveren Scientific Inc. announced delayed 10-Q filingOn 08/16/2023, Innoveren Scientific Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 16Innoveren Scientific Inc. announced delayed 10-Q filingOn 08/15/2024, Innoveren Scientific Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 18Innoveren Scientific Inc. announced delayed 10-Q filingOn 05/16/2024, Innoveren Scientific Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 03Innoveren Scientific Inc. announced delayed annual 10-K filingOn 04/02/2024, Innoveren Scientific Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Mar 06Innoveren Scientific Announces 510(K) Submission to U.S. Federal Food and Drug Administration for Skindisc(Tm) LiteInnoveren Scientific Inc. announced that it has submitted a 510(k) premarket filing to the U.S. Federal Food and Drug Administration (FDA) for its SkinDiscTM Lite product. SkinDiscTM Lite provides an active and protein-rich cellular matrix that is essential for structural support and cellular attachment during the wound-healing process that can be administered in an outpatient setting. The product maintains complete wound contact and depth fill during the healing process, resulting in rapid growth of the host tissue. SkinDiscTM Lite utilizes autologous platelet-rich plasma (PRP) and platelet poor plasma concentrate, from the patient's own body, helping to mitigate any potential rejection of the product.
お知らせ • Nov 17Innoveren Scientific Inc. announced delayed 10-Q filingOn 11/15/2023, Innoveren Scientific Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 18Innoveren Scientific Inc. announced delayed 10-Q filingOn 08/16/2023, Innoveren Scientific Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 16H-CYTE, Inc. announced delayed 10-Q filingOn 05/15/2023, H-CYTE, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Dec 30H-CYTE, Inc. (OTCQB: HCYT) completed the acquisition of SkinDisc from Tanya Rhodes, Brock Liden, Spencer T Brown and Spencer T Brown.H-CYTE, Inc. (OTCQB: HCYT) entered into a letter of intent to acquire SkinDisc from Tanya Rhodes, Brock Liden, Spencer T Brown and Spencer T Brown for $2.3 million on September 19, 2022. H-CYTE, Inc. (OTCQB: HCYT) entered into a definitive agreement to acquire SkinDisc from Tanya Rhodes and others on December 22, 2022. H-CYTE, Inc. will pay an aggregate of 123,153 shares and earn out payment of $1.615 million. Both parties board approved the transaction. The transaction is expected to close within the next 30 days. Arthur Marcus of Sichenzia Ross Ference acted as legal advisor to H-CYTE. H-CYTE, Inc. (OTCQB: HCYT) completed the acquisition of SkinDisc from Tanya Rhodes, Brock Liden, Spencer T Brown and Spencer T Brown on December 28, 2022.
お知らせ • Sep 20H-CYTE, Inc. (OTCQB: HCYT) entered into a letter of intent to acquire SkinDisc.H-CYTE, Inc. (OTCQB: HCYT) entered into a letter of intent to acquire SkinDisc on September 19, 2022. The transaction is expected to close within the next 30 days.
お知らせ • Jan 12H-CYTE, Inc. (OTCPK:HCYT) entered into a letter of intent to acquire Catheter Precision, Inc.H-CYTE, Inc. (OTCPK:HCYT) entered into a letter of intent to acquire Catheter Precision, Inc. on January 11, 2022. The transaction is subject to a definitive agreement and customary closing conditions. The transaction is expected to close in the first quarter of 2022.
お知らせ • Jun 30H-CYTE, Inc. Announces Publication of Positive Real-World Data Relating to the Use of Innovative Treatment at Helping Improve Overall Lung HealthH-CYTE, Inc. announced the publication of its clinical observational study titled, 'Longitudinal Assessment of FEV1 Change Following Autologous Cellular Therapy.' The study, published in the peer-reviewed Journal of Regenerative Medicine & Biology Research, relates to the Company’s innovative autologous treatment, and concludes that patients experienced a statistically significant improvement in pulmonary function at both 3 months and 12 months (FEV1 % predicted) and quality of life (CCQ score) post treatment. The study, which involved 281 participants with COPD (chronic obstructive pulmonary disease). demonstrated that 23% of patients saw an improvement in their lung function by at least 15% from baseline at 3 months post-treatment(FEV1 measures), and 29% of patients saw the same improvement at 12 months post-treatment. At 3 months and 12 months post-treatment, 64% and 67% of participants respectively, experienced a significant quality of life improvement. All participants tolerated the procedure well, and there were no reportable adverse or unexpected events. All participants were able to stay on their physician prescribed medications to manage their COPD. The efficacy, quality of life and safety shown in this study were above and beyond that achieved with their maintenance therapy. The data came from an externally validated patient database. The study design was observational following the intervention and therefore the limitations due to lack of a control group are recognized. To address this, a double blind randomized controlled trial involving the Company’s innovative PRP-PBMC therapy is currently being planned.
お知らせ • Jan 21H-Cyte, Inc. Announces Board ChangesOn January 12, 2021, Mr. William Horne stepped down as Chairman of the board of directors of H-Cyte, Inc. Mr. Horne will remain a member of the Board. On January 12, 2021, Mr. Ray Monteleone was appointed the new Chairman of the Board. Mr. Monteleone is a current member of the Board.
お知らせ • Oct 05H-CYTE, Inc. announced that it expects to receive $5.515765 million in funding from FWHC Bridge, LLC, FWHC Bridge Friends, LLCH-CYTE, Inc. (OTCPK:HCYT) announced that it has entered into a secured convertible note and warrant purchase agreement with FWHC Bridge, LLC and FWHC Bridge Friends, LLC to issue two secured convertible promissory notes in the original principal amount of $1,000,000 and $1,535,570 to FWHC Bridge, LLC and a secured convertible promissory note in the original principal amount of $100,000 to FWHC Bridge Friends, LLC to receive $2.635,570 in debt in the transaction. The notes are convertible into shares of the company. The company will issue common shares and option, warrant or other right to acquire another security in the transaction to receive $2,880,195 in the transaction pursuant to regulation D. The minimum investment accepted from any outside investor is $1,875. The company will receive 5,515,765 in total in the transaction.
お知らせ • Oct 02H-CYTE, Inc. announced that it has received $2.880195 million in funding from FWHC Bridge, LLC, FWHC Bridge Friends, LLCOn May 5, 2020, H-CYTE, Inc. (OTCPK:HCYT) closed the transaction. The company amended the terms of the transaction. The company entered into a secured convertible note and warrant purchase agreement with FWHC Bridge, LLC and FWHC Bridge Friends, LLC. The company issued two secured convertible promissory notes in the original principal amount of $1,000,000 and $1,535,570 to FWHC Bridge, LLC and a secured convertible promissory note in the original principal amount of $100,000 to FWHC Bridge Friends, LLC to receive $2.635,570 in debt in the transaction. The notes are convertible into shares of the company. The company received $5,515,765 in the transaction. The transaction included participation from 32 investors pursuant to regulation D.
お知らせ • Oct 01H-CYTE, Inc. Announces Executive ChangesH-CYTE, Inc. appointed Mr. Robert Greif as its and President. Mr. Greif is 55 years old. Prior to joining the Company, Mr. Greif was the Chief Commercial Officer and business development Leader at Axos Bio, Inc. from February 2019 to November 2019. At Axos, Mr. Greif built the north American commercial organization in preparation for the launch of a fist-in-class immunomodulatory. Prior to joining Atox, Mr. Greif led the commercial operations of rEvo Biologics, Inc., an orphan disease biotechnology company from May 2011 to February 2019. He also held a variety of business unit and commercial leadership roles at United health Group Incorporated, Boehringer Ingelheim Group and Sanofi SA. The Company believes that Mr. Greif's strong track record leading high-growth pharmaceutical and biotech businesses makes him qualified to serve in his role with the Company. On September 29, 2020, Ann Miller resigned as the Company's Chief Operating Officer. On September 29, 2020, Mr. William Horne resigned as the Company's President.
お知らせ • Sep 30H-CYTE, Inc. Announces Executive ChangesH-CYTE, Inc. announced that Robert Greif has been named the company’s new chief executive officer. Most recently, he was Chief Commercial Officer and Business Development Leader at Atox Bio. Greif joins H-CYTE as CEO and President effective September 29, 2020. He replaces William E. Horne, who is stepping down as CEO but will remain on the company’s Board of Directors.
